RALEIGH, N.C., Oct. 26, 2016 (GLOBE NEWSWIRE) — Hurricane Matthew has been devastating for North Carolina and its citizens, with the impact felt physically, emotionally and economically. As a member-owned financial cooperative based in North Carolina and serving 2.1 million members, State Employees’ Credit Union (SECU) took quick action to help members avoid the financial burden of costly fees during the immediate aftermath of the hurricane. The Credit Union waived over $293,000 in Non-Sufficient Funds (NSF) and returned check fees for members participating in SECU’s Another Chance Program over a four day period!
Since 2010, services like the Another Chance Program, the 5:30 p.m. “End of Business Day Cutoff” and Two-Way Text Messaging and Alerts have provided SECU members practical tools to manage their finances and avoid costly fees. Those enrolled in the Another Chance Program receive an alert when a check is attempting to post to their checking account when sufficient funds are not in place to pay the item. The alert notifies members that a deposit or transfer of funds is needed by 5:30 p.m. that same day in order to avoid being charged an NSF fee.
The Credit Union’s prompt action to ensure Another Chance items were not returned immediately following the storm gave members and their finances some much needed breathing room at a very difficult time. Over the four day period, the Credit Union paid more than 7,923 Another Chance items totaling over $1.8 million! Waiving SECU’s $12 NSF fees delivered more than $95,000 in savings, while members were also provided relief of $198,000 from returned check fees of merchant financial institutions.
“During a major weather emergency such as this, the safety and welfare of our members and employees are major concerns,” said Jennifer Hamrick, SECU Executive Vice President of Organizational Support. “Because power outages and flooding issues affected our members and local branches in numerous communities, paying these items was without a doubt the right thing to do. The credit union philosophy is ‘People Helping People®’ and our SECU mission is ‘Do the Right Thing!’ Keeping our members’ best interests at heart is what we do best!”
ABOUT SECUA not-for-profit financial cooperative owned by its members, SECU has been providing employees of the State of North Carolina and their families with consumer financial services for 79 years. The Credit Union also offers a diversified line of financial advisory services including retirement and education planning, tax preparation, insurance, trust and estate planning services, and investments through its partners and affiliated entities. SECU serves over 2 million members through 257 branch offices, nearly 1,100 ATMs, 24/7 Member Services via phone and a website, www.ncsecu.org.
Contact: Leigh Brady, EVP – Organizational Development 如何防范假冒WiFi热点-信息安全意识
Office: 919-807-8347 | email@example.com
RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2016 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that results from a study of galidesivir (formerly BCX4430) administered to Rhesus monkeys infected with Zika virus (ZIKV) will be presented as a late-breaker oral presentation at IDWeek 2016 taking place in New Orleans October 26-30, 2016.
The presentation titled “BCX4430, a Broad-Spectrum Adenosine Analog Direct-Acting Antiviral Drug, Abrogates Viremia in Rhesus Macaques Challenged with Zika Virus,” will be presented by James B. Whitney, PhD, Assistant Professor of Medicine, Harvard Medical School, and Principal Investigator in the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston. Dr. Whitney is also an Associate Member of The Ragon Institute of MGH, MIT and Harvard. The presentation will take place during the “Late Breaker Oral Abstracts” session on Saturday, October 29 at 11:10 AM Central Time.
A pre-clinical study in rhesus monkeys was completed to assess the safety and efficacy of galidesivir against ZIKV infection. Fifteen animals were subcutaneously challenged with Puerto Rican ZIKV isolate. Animals were distributed into three groups (n=5/group). Ninety minutes after challenge, group one received intramuscular (I.M.) doses of 100 mg/kg galidesivir BID on Day zero, followed by 25mg/kg BID for nine additional days. Group two received only 100 mg/kg galidesivir I.M. BID on day zero. Group three received vehicle only. Multiple endpoints, including ZIKV RNA levels in plasma, urine, saliva, and cerebrospinal fluid, were followed. Immune activation, complete blood counts, chemistries and galidesivir pharmacokinetics were longitudinally monitored throughout the study.
All control animals developed high-level viremia by day two post infection. In group one, the monkeys did not develop detectable plasma viremia. In group two, the monkeys were partially protected: two of five animals from this group had detectable plasma ZIKV RNA, but the onset was delayed and magnitude of viremia reduced compared to controls.
Galidesivir dosing in rhesus monkeys was well-tolerated and offered significant protection against ZIKV challenge. These results warrant further study.
About Galidesivir (BCX4430)Galidesivir is a broad spectrum antiviral in advanced development under the Animal Rule for the treatment of Ebola virus disease. A Phase 1 clinical safety and pharmacokinetics study in healthy subjects has been completed, and in animal studies, galidesivir has demonstrated survival benefits against a variety of serious pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses. Galidesivir has also demonstrated broad-spectrum activity in vitro against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses. BioCryst is developing galidesivir in collaboration with U.S. Government Agencies and other institutions.
About BioCryst Pharmaceuticals BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst currently has several ongoing development programs: BCX7353 and other second generation oral inhibitors of plasma kallikrein for hereditary angioedema, and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is a potential treatment for filoviruses. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza is BioCryst’s first approved product and is currently marketed in the U.S., Japan, Taiwan and Korea. Post-marketing commitment development activities are ongoing as well as activities to support regulatory approvals in other territories. For more information, please visit the Company’s website at www.BioCryst.com.
This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that the Company or its licensees may not commence as expected additional pre-clinical studies or human clinical trials; that the planned studies may not be successful or may not be successfully completed; that the FDA may require additional studies beyond those planned for galidesivir, or may not provide regulatory clearances which may result in delay of planned clinical trials, or may impose a clinical hold on galidesivir, or withhold market approval for galidesivir; that the Company may not be able to obtain additional funding for galidesivir development; that government funding or other contracts for galidesivir may have certain terms and conditions, including termination provisions, that subject the Company to additional risks; and/or that the Company may lose current funding for the program. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and current reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in BioCryst’s projections and forward-looking statements.
CONTACT: Robert Bennett, BioCryst Pharmaceuticals, +1-919-859-7910
MONTRÉAL, QUÉBEC–(Marketwired – 26 oct. 2016) – Bombardier apportera une superbe sélection d’avions au prochain congrès et salon de la National Business Aviation Association (NBAA), à Orlando (Floride), du 1er au 3 novembre 2016. Les biréacteurs d’affaires les plus évolués de l’avionneur seront en exposition statique, dont une maquette grandeur nature de l’avion Global 7000, ainsi que des avions Learjet, Challenger et Global de Bombardier.
Bombardier avions d’affaires accueillera les clients à son pavillon de l’aire d’exposition statique à l’aéroport d’affaires d’Orlando, où les avions Challenger 350 et Challenger 650 présenteront un revêtement de sol en pierre nouvellement installé pour l’office et la toilette. Bombardier tiendra également un événement spécial dans l’aire d’exposition statique, l’après-midi du dimanche 30 octobre, pour célébrer une importante annonce avec Zetta Jet.
Au centre des congrès d’Orlando, Bombardier annoncera les gagnants de ses Prix d’excellence annuels des établissements de service agréés, le mercredi 2 novembre, et fera également une série complète d’annonces techniques et opérationnelles durant toute la semaine. Ces prix témoignent de l’engagement de Bombardier à offrir à ses clients du service et du soutien de calibre mondial. Ils viennent saluer la qualité, le rendement et le service exceptionnels procurés aux clients de Bombardier dans les installations de révision générale et de maintenance en ligne du réseau de Bombardier.
À propos de Bombardier
Bombardier est le leader mondial de la fabrication d’avions et de trains. Regardant vers l’avenir tout en repoussant les limites du présent, Bombardier fait évoluer la mobilité en répondant à la demande mondiale en moyens de transport plus efficaces, plus durables et plus agréables. Notre leadership résulte d’un vaste éventail de véhicules, de services et, surtout, de nos employés.
Le siège social de Bombardier est situé à Montréal, au Canada. Nos actions (BBD) se négocient à la Bourse de Toronto, et nous sommes l’une des entreprises composant l’indice de durabilité Dow Jones Sustainability North America. Pour l’exercice clos le 31 décembre 2015, nos revenus ont totalisé 18,2 milliards $. Vous trouverez nouvelles et information à l’adresse bombardier.com ou en nous suivant sur Twitter : @Bombardier. 科华生物中期净利增长10.46%
Notes aux rédacteurs
Suivez @Bombardierjets sur Twitter pour obtenir les dernières nouvelles et mises à jour de Bombardier Avions d’affaires.
Pour recevoir nos communiqués de presse, visitez la section des fils RSS de notre site Web.
Bombardier, Challenger, Challenger 350, Challenger 650, Global, Global 7000, Learjet et L’évolution de la mobilité sont des marques de commerce de Bombardier Inc. ou de ses filiales.
DUNKIRK, N.Y., Oct. 26, 2016 (GLOBE NEWSWIRE) — Lake Shore Bancorp, Inc. (the “Company”) (NASDAQ:LSBK), the holding company for Lake Shore Savings Bank (the “Bank”), announced that the Company’s Board of Directors approved a $0.07 per share cash dividend on its common stock, payable on November 21, 2016, to shareholders of record as of November 10, 2016. Based on the Company’s closing stock price of $14.31 on October 25, 2016, the implied dividend yield for the Company’s common stock is currently 1.96%.
Lake Shore, MHC (the “MHC”), which holds 3,636,875 shares, or approximately 59.6% of the Company’s total outstanding stock, elected to waive its right to receive this cash dividend of approximately $255,000. On March 2, 2016, the MHC received the non-objection of the Federal Reserve Bank of Philadelphia to waive its right to receive dividends paid by the Company during the twelve months ending February 2, 2017, aggregating up to $0.28 per share.
Company ProfileLake Shore Bancorp, Inc. (NASDAQ:LSBK) is the mid-tier holding company of Lake Shore Savings Bank, a federally chartered, community-oriented financial institution headquartered in Dunkirk, New York. The Bank has eleven full-service branch locations in Western New York, with five locations in Chautauqua County, New York and six locations in Erie County, New York. The Company had total assets of $478.4 million and total deposits of $374.5 million as of September 30, 2016. The Bank offers a broad range of retail and commercial lending and deposit services. The Company’s common stock is traded on the NASDAQ Global Market as “LSBK”. Additional information about the Company is available at www.lakeshoresavings.com.
Safe-HarborThis release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, that are based on current expectations, estimates and projections about the Company’s and the Bank’s industry, and management’s beliefs and assumptions. Words such as anticipates, expects, intends, plans, believes, estimates and variations of such words and expressions are intended to identify forward-looking statements. Such statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to forecast. Therefore, actual results may differ materially from those expressed or forecast in such forward-looking statements. The Company and Bank undertake no obligation to update publicly any forward-looking statements, whether as a result of new information or otherwise.
Rachel A. Foley
Chief Financial Officer and Treasurer
Lake Shore Bancorp, Inc.
31 East Fourth Street
Dunkirk, New York 14048 浙大兰德(08106)首季亏损扩大至265.5万人币不派息
OTTAWA, ONTARIO–(Marketwired – Oct. 26, 2016) – 1,000 hospital staff from across Ontario including some from Ottawa will rally on Thursday, October 27, 2016 at Kingston General Hospital (KGH) calling for an end to Ontario’s underfunding of hospital care.
Ontario has fallen far behind other provinces on hospital spending since the Liberals were elected provincially in 2003. The province has been cutting hospital budgets in real terms for 8 years.
“We are asking for an immediate end to the provincial funding cuts that are choking the life from Ontario hospitals,” says Canadian Union of Public Employees (CUPE) President, Mark Hancock one of the rally’s keynote speakers.
Ontario spends 25.3 per cent less for hospitals than the other provinces, which translates to a $4.8 billion annual funding shortfall, leading to “unacceptably high readmission rates, bed shortages and six hours less nursing care for each Ontario patient compared with the rest of Canada,” says Hancock.
In addition to those going from northeastern Ontario, Hospital workers attending the noon rally (on the Stuart Street side of KGH) are coming from Smiths Falls, Perth, Pembroke, Cornwall, Sudbury, North Bay, New Liskeard, Guelph, Hamilton, Stratford and throughout the Greater Toronto Area. They will first meet at City Park at 11:30 a.m. and march along Stuart Street to KGH.
Hospitals across Ontario are cutting beds, services and staff. Ontario now has the fewest hospital beds to population of any province in Canada and the fewest staff for those beds.
“We believe that the merger of Kingston’s hospitals is designed to further cut beds and services, even though KGH has been without an available bed for up to 25 days in a row during the last year. Like most Ontario hospitals, Kingston hospitals simply do not have enough beds and staffing capacity for the number of patients needing care,” says Michael Hurley president of CUPE’s Ontario Council of Hospital Unions/CUPE.
Hospital staff represented by CUPE will be stepping up protests over provincial hospital funding cuts with demonstrations in 2017 in Hamilton on February 6, Kenora on April 26, Sudbury on June 15 and in Ottawa on October 19.
REYKJAVÍK – 26. október 2016 – Uppgjör þriðja ársfjórðungs og fyrstu níu mánuði 2016
Sala á vöru og þjónustu nam 3.429 mkr á þriðja ársfjórðungi (13,6% tekjuvöxtur frá F3 2015) og 10.555 mkr á fyrstu níu mánuðum ársins (9,2% tekjuvöxtur frá fyrstu níu mánuðum 2015) [F3 2015: 3.019 mkr, 9M 2015: 9.669 mkr]
Framlegð nam 860 mkr (25,1%) á þriðja ársfjórðungi og 2.676 (25,4%) fyrstu níu mánuði 2016 [F3 2015: 828 mkr (27,4%), 9M 2015: 2.465 mkr (25,5%)]
EBITDA nam 247 mkr (7,2%) á þriðja ársfjórðungi og 686 mkr (6,5%) fyrstu níu mánuði ársins [F3 2015: 240 mkr (8,0%), 9M 2015: 693 mkr (7,2%)]
Heildarhagnaður á þriðja ársfjórðungi var 93 mkr og 204 mkr fyrstu níu mánuði ársins [F3 2015: 82 mkr, 9M 2015: 193 mkr] 手把手教您建立线上培训帝国。
Eiginfjárhlutfall var 32,5% í lok þriðja ársfjórðungs en var 30,8% í lok annars ársfjórðungs
Applicon AB selur og innleiðir kjarnabankakerfi hjá SBAB Bank AB í Svíþjóð
Finnur Oddsson, forstjóri:
„Rekstur Nýherjasamstæðunnar var á áætlun á þriðja fjórðungi og jákvætt að tekjuvöxtur var meiri á fjórðungnum heldur en fyrripart árs. Afkoman á árinu er viðunandi, svipuð og í fyrra, en það sem við horfum einnig jákvætt til er það að vaxtaberandi skuldir eru að lækka umtalsvert og eiginfjárstaða félagsins heldur áfram að styrkjast.
Almennt gengur rekstur Nýherja og dótturfélaga vel, sérstaklega í hugbúnaðartengdri starfsemi þar sem tekjuvöxtur hefur verið umtalsverður. Til að mynda voru tekjur Tempo á fjórðungnum USD 3,2 m og USD 9,4m á árinu, sem er 43% aukning á þriðja ársfjórðung. Við sjáum svo einnig töluverða tekjuaukningu hjá Applicon AB, TM Software og hugbúnaðarsviði Nýherja. Það er því góð eftirspurn eftir okkar lausnum og eitt helsta viðfangsefnið okkar er að ná að anna henni en jafnframt gæta að kostnaði í rekstrinum.
Það voru svo afar góð tíðindi að Applicon í Svíþjóð gekk frá stórum samningi í lok fjórðungsins um sölu og innleiðingu á SAP kjarnabankalausnum fyrir SBAB Bank, sem er 5. stærsti bankinn í Svíþjóð. Þetta er tímamótasamningur sem hefur verið lengi í undirbúningi og byggir á þekkingu og lausnum sem þróaðar hafa verið innan okkar vébanda á undanförnum árum. Að innleiðingu lokinni mun Applicon reka og viðhalda bankakerfum fyrir tvo af tíu stærstu bönkum í Svíþjóð, en í því felst mikil viðurkenning á þeirri reynslu og þeim gæðum hugbúnaðarlausna sem Applicon hefur yfir að ráða fyrir fjármálamarkaði.
Öll félög samstæðunnar skila jákvæðri afkomu og horfur í rekstri eru ágætar.“
Finnur Oddsson forstjóri í síma 862-0310 eða firstname.lastname@example.org og Gunnar Petersen framkvæmdastjóri fjármálasviðs í síma 825-9001 eða email@example.com.
NEW YORK, Oct. 26, 2016 (GLOBE NEWSWIRE) — The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Xerox Corporation (NYSE:XRX) between April 23, 2012 and October 23, 2015. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. To get more information go to:
or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that during the Class Period the Company violated securities laws by failing to disclose that: (a) the Company’s existing Health Enterprise projects were experiencing major delays and cost overruns; and (b) the Company would be unable to deliver Health Enterprise implementations at sustainable profits.
On October 26, 2015, Xerox released third quarter 2015 financial results that missed analysts’ estimates due in part due to a $385 million pre-tax charge and lost revenues relating to assets and unrecoverable costs associated with its Health Enterprise implementation projects and the termination of Health Enterprise’s California and Montana projects. Following this news, shares of Xerox fell from a class period high of $13.57 per share on December 5, 2014, to a close of just $9.01 per share on October 27, 2015.
If you suffered a loss in Xerox Corporation you have until December 23, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. 2016株洲茶陵农商银行员工招聘公告
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171